Bayer's Weinand On Pricing, Payers And Pipelines
Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."
You may also be interested in...
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.
Bayer's PI3 kinase inhibitor copanlisib now has accelerated approval in a common type of non-Hodgkin lymphoma, but the drug's competitive profile still awaits Phase III data.
A large new market in coronary artery and peripheral arterial disease beckons after Xarelto showed a 24% reduction in the risk of major cardiac events, a benefit that may outweigh the increase in major bleeding.